abstract |
The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime-boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting. |